race oncology highlights impressive bisantrene clinical data
Published 9 months ago • 389 plays • Length 8:00Download video MP4
Download video MP3
Similar videos
-
6:42
race oncology looks to accelerate clinical development of bisantrene
-
4:36
race oncology partners with george clinical for rc220 bisantrene trials
-
5:15
race oncology completes glp studies for rc220 bisantrene; closer to human trials
-
6:49
race oncology receives positive results from aml trial of bisantrene
-
11:34
the aging narcissist, what you need to know
-
17:40
race leadership team strengthened
-
5:19
cramer: this biotech stock could be worth over $100 billion on an fda approval
-
5:10
race oncology receives fda orphan drug designation extension for bisantrene rc220
-
0:49
race oncology reports bisantrene shows potent anti-cancer activity
-
0:36
race trials new zantrene drug for extramedullary acute myeloid leukaemia (emd aml) – animation
-
0:47
race oncology bisantrene production
-
11:26
race oncology's daniel tillett details positive preclinical results for bisantrene in breast cancer
-
2:45
race oncology welcomes positive pre-ind meeting for zantrene
-
4:07
usa: race oncology on proactive investors
-
8:05
race oncology receives us fda rare paediatric disease designation for aml treatment
-
3:39
executive interview - race oncology
-
1:44
what is race oncology?
-
41:56
race oncology agm 2020
-
27:43
race presents at ird invest
-
33:20
sharewise webinar with race oncology ceo daniel tillett